ANDA 216125, held by Bamf. Fludeoxyglucose F-18.
As of Nov 16, 2026, ANDA 216125 (Fludeoxyglucose F18), held by Bamf, was first approved by FDA on Mar 11, 2025, with 0 approved supplements and 0 published complete response letters.
Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fludeoxyglucose F1820-400mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters